精神分裂症的神经影像学生物标志物
本文综述了精神分裂症神经影像学生物标志物的候选机制,包括多巴胺过度活跃、N-甲基-D-天冬氨酸受体功能低下、海马过度活跃、免疫失调、连接异常和皮层灰质体积减少。作者讨论了用于疾病风险、诊断、靶点 engagement 和治疗反应的候选影像标志物,并指出未满足的需求和推进生物标志物开发的策略。目前尚无客观生物学指标可用于诊断或治疗决策。
要点
- 目前精神分裂症尚无客观生物标志物用于诊断或治疗决策。
- 神经影像学可捕捉分子、细胞靶点或脑环路表型变化,有潜力成为生物标志物。
- 候选机制包括多巴胺过度活跃、NMDA受体功能低下、海马过度活跃、免疫失调、连接异常和灰质体积减少。
核心结论
- 神经影像学生物标志物有潜力反映精神分裂症病理生理机制,并作为中间或替代终点。
- 有效生物标志物可验证新治疗靶点、预测反应、辅助患者选择、确定治疗方案并提供个体化治疗依据。
研究设计与样本
- 本文为综述,讨论了一系列机制上合理的神经影像学生物标志物候选者。
主要发现
- 候选机制包括多巴胺过度活跃、N-甲基-D-天冬氨酸受体功能低下、海马过度活跃、免疫失调、连接异常和皮层灰质体积减少。
- 综述聚焦于用于疾病风险、诊断、靶点 engagement 和治疗反应的推定神经影像学生物标志物。
临床怎么用
- 当前尚无客观生物标志物可指导精神分裂症的诊断或治疗决策。
- 神经影像学生物标志物有望用于验证治疗靶点、预测治疗反应和辅助个体化治疗选择。
局限性
- 文中指出生物标志物开发存在未满足的需求,并讨论了推进策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Schizophrenia is a complex neuropsychiatric syndrome with a heterogeneous genetic, neurobiological, and phenotypic profile. Currently, no objective biological measures-that is, biomarkers-are available to inform diagnostic or treatment decisions. Neuroimaging is well positioned for biomarker development in schizophrenia, as it may capture phenotypic variations in molecular and cellular disease targets, or in brain circuits. These mechanistically based biomarkers may represent a direct measure of the pathophysiological underpinnings of the disease process and thus could serve as true intermediate or surrogate endpoints. Effective biomarkers could validate new treatment targets or pathways, predict response, aid in selection of patients for therapy, determine treatment regimens, and provide a rationale for personalized treatments. In this review, the authors discuss a range of mechanistically plausible neuroimaging biomarker candidates, including dopamine hyperactivity, N-methyl-d-aspartate receptor hypofunction, hippocampal hyperactivity, immune dysregulation, dysconnectivity, and cortical gray matter volume loss. They then focus on the putative neuroimaging biomarkers for disease risk, diagnosis, target engagement, and treatment response in schizophrenia. Finally, they highlight areas of unmet need and discuss strategies to advance biomarker development.
引用
- Kraguljac NV, McDonald WM, Widge AS, et al. Neuroimaging Biomarkers in Schizophrenia. Am J Psychiatry. 2021. PMID: 33397140. doi:10.1176/appi.ajp.2020.20030340
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。